Study of Enfortumab Vedotin Plus Avelumab for Advanced Penile Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older with penile squamous cell carcinoma (the most common type of penile cancer).
- Your cancer must have spread or be in a stage that can't be removed completely with surgery.
- You cannot have had any prior chemotherapy or immunotherapy for advanced penile cancer (cancer that has spread).
- You need to have a tumor sample available for testing (to check for PD-L1 and HPV).
- Your overall health should be good enough that you can care for yourself (ECOG performance status 0–2).
- You must have normal organ function (kidneys, liver, blood counts) and no major heart problems or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs given before surgery for penile cancer that has spread to nearby tissues or lymph nodes. The goal is to see if this combination can shrink tumors and improve outcomes. The drugs work by helping the immune system attack cancer cells and delivering chemotherapy directly to them.
This trial tests a drug called enfortumab vedotin for people with advanced penile cancer (squamous cell carcinoma) that has spread or cannot be surgically removed. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Hear when a new Penile Squamous Cell Carcinoma (PSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.